Johnson & Johnson: Recovering From A Deep Correction, Beats Earnings Estimates

Johnson & Johnson (NYSE:JNJ) closed Friday at $130.62, down 6.5% year to date and in correction territory, 11.9% below its all-time intraday high of $148.33 on Jan. 17. From this high to the Feb. 5 low of $122.15, the stock crashed by 17.6%. Since then, the stock is in recovery mode, up 6.9%.

JNJ beat earnings estimates by 5 cents earning $2.06 a share and traded as high as $133.50 in early pre-market trading.

The Dow Jones Industrial Average ended Friday down 1.5% year to date and set its all-time intraday of 26,616.71 on Jan. 26 and is 8.5% below this high. The J&J recovery outperforms the Dow which is 4.4% above its April 2 year-to-date low of 23,344.52.

J&J has been in the news recently.

The pharmaceutical giant and healthcare products company was ordered to pay $80 million in the talcum powder case. J&J's Baby Powder was said to have caused asbestos-related cancers and this case ended with a $117 million verdict. J&J is also challenged by competition from Eli Lilly and Company (NYSE:LLY) in the battle to treat diabetes and other ailments. These events did not have a significant impact on earnings.

READ FULL ARTICLE HERE